S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
S&P 500   5,253.45 (+0.09%)
DOW   39,787.01 (+0.07%)
QQQ   444.17 (-0.15%)
AAPL   171.33 (-1.14%)
MSFT   420.18 (-0.30%)
META   488.44 (-1.10%)
GOOGL   150.74 (-0.09%)
AMZN   180.47 (+0.36%)
TSLA   177.13 (-1.50%)
NVDA   905.24 (+0.30%)
NIO   4.55 (-2.57%)
AMD   180.92 (+0.74%)
BABA   72.50 (+1.27%)
T   17.67 (+0.68%)
F   13.23 (+1.30%)
MU   117.88 (-1.06%)
CGC   9.05 (-5.24%)
GE   174.97 (-2.86%)
DIS   122.62 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.05 (+0.97%)
PYPL   67.30 (+1.10%)
XOM   116.07 (+0.96%)
NASDAQ:ISRG

Intuitive Surgical (ISRG) Stock Price, News & Analysis

$397.70
-2.40 (-0.60%)
(As of 01:51 PM ET)
Today's Range
$397.38
$402.50
50-Day Range
$358.88
$400.59
52-Week Range
$246.63
$403.76
Volume
352,606 shs
Average Volume
1.66 million shs
Market Capitalization
$140.96 billion
P/E Ratio
79.07
Dividend Yield
N/A
Price Target
$371.60

Intuitive Surgical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.79 Rating Score
Upside/​Downside
6.8% Downside
$371.60 Price Target
Short Interest
Healthy
1.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.94mentions of Intuitive Surgical in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$95.93 M Sold Last Quarter
Proj. Earnings Growth
17.65%
From $4.93 to $5.80 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.71 out of 5 stars

Medical Sector

59th out of 939 stocks

Surgical Appliances & Supplies Industry

3rd out of 18 stocks

ISRG stock logo

About Intuitive Surgical Stock (NASDAQ:ISRG)

Intuitive Surgical, Inc. is a leading medical technology company specializing in robotic-assisted surgical systems. Founded in 1995, the company's mission is to improve patient outcomes through the use of innovative technology and minimally invasive surgical techniques. Headquartered in Sunnyvale, California, Intuitive Surgical operates globally, serving healthcare professionals and patients in over 60 countries.

Intuitive Surgical's flagship product is the da Vinci Surgical System, a robotic platform that enables surgeons to perform complex procedures with enhanced precision, control, and visualization. The system consists of robotic arms controlled by the surgeon, along with a high-definition 3D camera and specialized surgical instruments. This advanced technology allows for smaller incisions, reduced scarring, shorter recovery times, and improved clinical outcomes.

The company's target market primarily includes hospitals and surgical centers specializing in urology, gynecology, general, and thoracic surgery. Intuitive Surgical has established itself as a leader in these fields and has a strong customer base, including prestigious medical institutions and renowned surgeons. The company's dedication to innovation and patient care has garnered numerous accolades, including recognition as one of Fortune's "World's Most Admired Companies" in the healthcare industry.

Intuitive Surgical is led by an experienced management team committed to driving the company's growth and maintaining its position as a leader in surgical robotics. Dr. Gary Guthart is the Chief Executive Officer and has been instrumental in guiding the company's strategic direction. Under his leadership, Intuitive Surgical has expanded its product portfolio, entered new markets, and achieved remarkable financial success.

Intuitive Surgical has consistently delivered strong financial performance over the past few years. The company's revenue has experienced steady growth, reaching $6.22 billion in the latest fiscal year. With a strong focus on operational efficiency, Intuitive Surgical has maintained healthy profit margins, enabling it to invest in research and development and expand its market reach.

The company has a solid balance sheet with manageable debt levels. This provides stability and financial flexibility for future investments and acquisitions. Intuitive Surgical's financial performance is notably impressive compared to industry benchmarks, reflecting its strong market position and competitive advantage.

Intuitive Surgical commands a premium compared to its industry peers. The company's price-to-earnings ratio, a commonly used valuation measure, is higher than average due to its strong growth prospects and dominant market position. Investors have recognized the company's innovation and potential for long-term success, contributing to its higher valuation.

Intuitive Surgical has exhibited remarkable stock performance in recent years. The company's share price has experienced significant growth, reflecting investor confidence in its business model and growth potential. Notably, the stock has outperformed broader market indices and many of its industry peers.

Intuitive Surgical operates in the rapidly evolving field of surgical robotics, which is transforming the healthcare landscape. The industry is characterized by intense competition, with major players including Medtronic, Johnson & Johnson, and Stryker Corporation. These companies continually invest in research and development to enhance their robotic surgical systems and expand their market presence.

Regulatory and political factors also play a significant role in the industry. Government agencies, such as the U.S. Food and Drug Administration (FDA), regulate the approval and safety of robotic surgical systems. Changes in regulations or introducing new policies can impact the industry landscape and market access for companies like Intuitive Surgical.

Despite the competitive landscape, Intuitive Surgical maintains a solid competitive advantage. The company's pioneering da Vinci Surgical System has established a dominant position in the market, with a large installed base worldwide. This gives Intuitive Surgical a significant edge in terms of customer loyalty and brand recognition. Additionally, the company's focus on continuous innovation and product development enables it to stay ahead of the competition.

Acquisitions and strategic partnerships offer growth opportunities for Intuitive Surgical. The company has a strong balance sheet enabling it to pursue strategic acquisitions that complement its existing product portfolio or provide access to new markets. Collaborating with other medical technology companies or research institutions can also fuel innovation and open doors to novel surgical solutions.

Like any company operating in the healthcare industry, Intuitive Surgical faces various risks and challenges. One significant risk is the potential for changes in healthcare policies and reimbursement rates. Government policies can directly impact the adoption and utilization of robotic surgical systems, which could affect the demand for Intuitive Surgical's products.

Another challenge is emerging new technologies or surgical techniques that may compete with or disrupt the robotic-assisted surgery market. Technological advancements in artificial intelligence and virtual reality could offer alternative solutions to traditional surgical procedures. Intuitive Surgical must stay at the forefront of innovation and adapt its offerings to remain competitive.

Additionally, the company faces the risk of product recalls or safety concerns. As robotic surgical systems become more complex, ensuring their reliability and patient safety becomes paramount. Intuitive Surgical must continue to invest in quality control measures, regulatory compliance, and ongoing training for surgeons to mitigate these risks.

ISRG Stock Price History

ISRG Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
ISRG Mar 2024 402.500 call
ISRG Mar 2024 377.500 put
See More Headlines
Receive ISRG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intuitive Surgical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/23/2024
Today
3/28/2024
Next Earnings (Estimated)
4/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ISRG
CUSIP
46120E60
Employees
13,676
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$371.60
High Stock Price Target
$435.00
Low Stock Price Target
$270.00
Potential Upside/Downside
-7.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
19 Analysts

Profitability

Net Income
$1.80 billion
Pretax Margin
27.50%

Debt

Sales & Book Value

Annual Sales
$7.12 billion
Cash Flow
$5.54 per share
Book Value
$38.03 per share

Miscellaneous

Free Float
351,613,000
Market Cap
$141.82 billion
Optionable
Optionable
Beta
1.36

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Intuitive Surgical Stock? ISRG Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Intuitive Surgical was last updated on Monday, March 25, 2024 at 11:59 AM.

Pros

Here are some ways that investors could benefit from investing in Intuitive Surgical, Inc.:

  • Intuitive Surgical, Inc. develops and manufactures products that enable physicians to enhance the quality of minimally invasive care, which is a growing trend in healthcare due to its benefits of faster recovery times and reduced complications.
  • The company offers the da Vinci Surgical System, a cutting-edge technology that allows for complex surgeries using a minimally invasive approach, attracting healthcare providers looking to offer advanced surgical options.
  • Intuitive Surgical's Ion endoluminal system expands its commercial offerings beyond surgery into diagnostic procedures, tapping into the increasing demand for minimally invasive biopsies in the medical field.
  • Recent positive institutional ownership trends indicate confidence from large investors in the company's future growth potential, which can be a reassuring sign for individual investors.
  • Despite fluctuations, the current stock price of Intuitive Surgical, Inc. reflects a stable performance and growth prospects, making it an attractive investment opportunity for those seeking long-term gains.

Cons

Investors should be bearish about investing in Intuitive Surgical, Inc. for these reasons:

  • Intuitive Surgical, Inc. faces competition in the medical technology sector, which could impact its market share and pricing power, potentially affecting its profitability in the long run.
  • The reliance on a few key products, such as the da Vinci Surgical System, exposes the company to risks associated with technological advancements or regulatory changes that could disrupt its product offerings.
  • Market volatility and economic uncertainties can influence the demand for expensive medical devices like those offered by Intuitive Surgical, making the company susceptible to fluctuations in healthcare spending.
  • Investing in healthcare companies like Intuitive Surgical carries inherent risks related to regulatory approvals, clinical trials, and potential litigation, which can impact the company's financial performance and reputation.
  • While the company has shown resilience, any unforeseen events, such as supply chain disruptions or adverse healthcare policies, could pose challenges to Intuitive Surgical's operations and financial stability.

ISRG Stock Analysis - Frequently Asked Questions

Should I buy or sell Intuitive Surgical stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intuitive Surgical in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ISRG shares.
View ISRG analyst ratings
or view top-rated stocks.

What is Intuitive Surgical's stock price target for 2024?

19 Wall Street analysts have issued 12 month price targets for Intuitive Surgical's stock. Their ISRG share price targets range from $270.00 to $435.00. On average, they expect the company's stock price to reach $371.60 in the next twelve months. This suggests that the stock has a possible downside of 6.8%.
View analysts price targets for ISRG
or view top-rated stocks among Wall Street analysts.

How have ISRG shares performed in 2024?

Intuitive Surgical's stock was trading at $337.36 at the beginning of the year. Since then, ISRG stock has increased by 18.1% and is now trading at $398.58.
View the best growth stocks for 2024 here
.

Are investors shorting Intuitive Surgical?

Intuitive Surgical saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,570,000 shares, an increase of 8.2% from the February 29th total of 3,300,000 shares. Based on an average daily volume of 1,630,000 shares, the short-interest ratio is presently 2.2 days.
View Intuitive Surgical's Short Interest
.

When is Intuitive Surgical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 16th 2024.
View our ISRG earnings forecast
.

How were Intuitive Surgical's earnings last quarter?

Intuitive Surgical, Inc. (NASDAQ:ISRG) posted its quarterly earnings results on Tuesday, January, 23rd. The medical equipment provider reported $1.60 EPS for the quarter, beating the consensus estimate of $1.48 by $0.12. The medical equipment provider earned $1.93 billion during the quarter, compared to analyst estimates of $1.89 billion. Intuitive Surgical had a trailing twelve-month return on equity of 13.11% and a net margin of 25.24%. The company's revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.91 EPS.
Read the conference call transcript
.

When did Intuitive Surgical's stock split?

Intuitive Surgical's stock split on the morning of Tuesday, October 5th 2021. The 3-1 split was announced on Thursday, August 5th 2021. The newly created shares were payable to shareholders after the closing bell on Monday, October 4th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Intuitive Surgical issued on next quarter's earnings?

Intuitive Surgical updated its fourth quarter 2023 earnings guidance on Tuesday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.9 billion-$1.9 billion, compared to the consensus revenue estimate of $1.9 billion.

What is Gary S. Guthart's approval rating as Intuitive Surgical's CEO?

431 employees have rated Intuitive Surgical Chief Executive Officer Gary S. Guthart on Glassdoor.com. Gary S. Guthart has an approval rating of 99% among the company's employees. This puts Gary S. Guthart in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Intuitive Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intuitive Surgical investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Salesforce (CRM), PayPal (PYPL), Walt Disney (DIS), Boeing (BA), Mastercard (MA) and Adobe (ADBE).

Who are Intuitive Surgical's major shareholders?

Intuitive Surgical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.62%), Price T Rowe Associates Inc. MD (4.82%), Capital World Investors (2.05%), Edgewood Management LLC (1.46%), Fisher Asset Management LLC (1.28%) and Fisher Asset Management LLC (1.27%). Insiders that own company stock include Alan J Levy, Amal M Johnson, Amy L Ladd, Craig H Barratt, Craig H Barratt, Curet Myriam, David J Rosa, David J Rosa, Fredrik Widman, Gary S Guthart, Jamie Samath, Keith R Leonard, Mark Brosius, Mark J Rubash, Mark J Rubash, Marshall Mohr, Myriam Curet, Reiter Kara Andersen and Robert Desantis.
View institutional ownership trends
.

How do I buy shares of Intuitive Surgical?

Shares of ISRG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Intuitive Surgical have any subsidiaries?
The following companies are subsidiares of Intuitive Surgical: Computer Motion, Intuitive Surgical AB, Intuitive Surgical ApS, Intuitive Surgical Australia Proprietary Limited, Intuitive Surgical BV, Intuitive Surgical Brasil Importacao E Comercio De Equipamentos Cirurgicos Ltda, Intuitive Surgical Canada Inc, Intuitive Surgical Deutschland GmbH, Intuitive Surgical Fosun HongKong Co Ltd, Intuitive Surgical Fosun Medical Technology Shanghai Co Ltd, Intuitive Surgical GK, Intuitive Surgical HK Limited, Intuitive Surgical Holdings LLC, Intuitive Surgical India Private Limited, Intuitive Surgical International BV, Intuitive Surgical International Finance LLC, Intuitive Surgical Ireland Limited, Intuitive Surgical Israel Ltd, Intuitive Surgical Korea Limited, Intuitive Surgical Limited, Intuitive Surgical Medical Device Science & Technology Shanghai Co Ltd, Intuitive Surgical Medical Device Taiwan Ltd, Intuitive Surgical Operations Inc, Intuitive Surgical Optics Gmbh, Intuitive Surgical Pte Ltd, Intuitive Surgical S de R L de CV, Intuitive Surgical SAS, Intuitive Surgical SPRL, Intuitive Surgical Sarl, Intuitive Surgical Sarl Taiwan Branch, Intuitive Surgical Service Optics Inc, Intuitive Surgical Spain SL, Intuitive Surgical Turkey Medikal Cihaz Ticaret Limited Serketi, Intuitive Surgical sro, Intuitive Ventures Fund I LLC, NeoGuide Systems, Orpheus Medical, Orpheus Medical Gmbh, Orpheus Medical Inc, Orpheus Medical Ltd, Orpheus Medical USA Inc, and Scholly Micro Optics Gmbh.
Read More
This page (NASDAQ:ISRG) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners